^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MEDI-547

    i
    Other names: MEDI-547
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    Microtubule inhibitor, EphA2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    4years
    Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer. (PubMed, Clin Cancer Res)
    These data demonstrate that MEDI0457 can generate durable HPV16/18 antigen-specific peripheral and tumor immune responses. This approach may be used as a complementary strategy to PD-1/PD-L1 inhibition in HPV-associated HNSCCa to improve therapeutic outcomes.
    Journal
    |
    CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
    |
    MEDI-547 • MEDI0457